Comparative Pharmacology
Head-to-head clinical analysis: AIMOVIG versus MYZILRA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AIMOVIG versus MYZILRA.
AIMOVIG vs MYZILRA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AIMOVIG (erenumab) is a human monoclonal antibody that binds to the calcitonin gene-related peptide (CGRP) receptor and antagonizes CGRP receptor function. CGRP is a neuropeptide involved in the pathophysiology of migraine; its release leads to vasodilation and activation of pain pathways.
MYZILRA is a monoclonal antibody that binds to the neonatal Fc receptor (FcRn), reducing IgG recycling and lowering circulating IgG levels, including pathogenic autoantibodies.
70 mg subcutaneously once monthly; some patients may benefit from 140 mg subcutaneously once monthly.
10 mg intravenously once daily for 12 weeks, followed by 10 mg subcutaneously every 8 weeks for maintenance.
None Documented
None Documented
28 days (range 23-31 days) in healthy volunteers; supports monthly subcutaneous dosing.
Terminal elimination half-life is 22 hours; permits once-daily dosing in most patients.
Elimination via proteolytic catabolism; no renal or biliary excretion of intact antibody.
Renal elimination of unchanged drug accounts for 70% of clearance; biliary/fecal excretion accounts for 25%; 5% metabolized.
Category C
Category C
CGRP Antagonist
CGRP Antagonist